WallStreetZenWallStreetZen

NASDAQ: SGP
Spyglass Pharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SGP

Based on 1 analyst offering 12 month price targets for Spyglass Pharma Inc

Min Forecast
$39.00+44.07%
Avg Forecast
$39.00+44.07%
Max Forecast
$39.00+44.07%

Should I buy or sell SGP stock?

Based on 1 analyst offering ratings for Spyglass Pharma Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SGP's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates SGP as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their SGP stock forecasts and price targets.

SGP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-14

1 of 1

Forecast return on equity

Is SGP forecast to generate an efficient return?

Company
-41.73%
Industry
22.21%
Market
168.26%
SGP's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SGP forecast to generate an efficient return on assets?

Company
-39.83%
Industry
23.81%
SGP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SGP earnings per share forecast

What is SGP's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$2.43
Avg 2 year Forecast
-$2.84
Avg 3 year Forecast
-$3.09

SGP revenue forecast

What is SGP's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

SGP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SGP$27.07$39.00+44.07%Buy
RIGL$48.18$71.67+48.75%Buy
JBIO$14.42$51.20+255.06%Strong Buy
ALMS$7.10$29.20+311.27%Strong Buy
TBPH$17.03$17.00-0.18%Hold
View Top Biotech Stocks

Spyglass Pharma Stock Forecast FAQ

Is Spyglass Pharma Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: SGP) stock is to Buy SGP stock.

Out of 1 analyst, 0 (0%) are recommending SGP as a Strong Buy, 1 (100%) are recommending SGP as a Buy, 0 (0%) are recommending SGP as a Hold, 0 (0%) are recommending SGP as a Sell, and 0 (0%) are recommending SGP as a Strong Sell.

If you're new to stock investing, here's how to buy Spyglass Pharma stock.

What is SGP's earnings growth forecast for 2026-2028?

(NASDAQ: SGP) Spyglass Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.78%.

Spyglass Pharma's earnings in 2026 is N/A.On average, 7 Wall Street analysts forecast SGP's earnings for 2026 to be -$81,435,794, with the lowest SGP earnings forecast at -$84,242,080, and the highest SGP earnings forecast at -$73,050,386. On average, 7 Wall Street analysts forecast SGP's earnings for 2027 to be -$95,079,225, with the lowest SGP earnings forecast at -$113,087,617, and the highest SGP earnings forecast at -$68,381,048.

In 2028, SGP is forecast to generate -$103,260,601 in earnings, with the lowest earnings forecast at -$135,049,560 and the highest earnings forecast at -$65,782,140.

What is SGP's revenue growth forecast for 2026-2028?

(NASDAQ: SGP) Spyglass Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.9%.

Spyglass Pharma's revenue in 2026 is N/A.On average, 6 Wall Street analysts forecast SGP's revenue for 2026 to be $0, with the lowest SGP revenue forecast at $0, and the highest SGP revenue forecast at $0. On average, 6 Wall Street analysts forecast SGP's revenue for 2027 to be $0, with the lowest SGP revenue forecast at $0, and the highest SGP revenue forecast at $0.

In 2028, SGP is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is SGP's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: SGP) forecast ROA is -39.83%, which is lower than the forecast US Biotechnology industry average of 23.81%.

What is SGP's Price Target?

According to 1 Wall Street analyst that have issued a 1 year SGP price target, the average SGP price target is $39.00, with the highest SGP stock price forecast at $39.00 and the lowest SGP stock price forecast at $39.00.

The Wall Street analyst predicted that Spyglass Pharma's share price could reach $39.00 by Aug 14, 2027. The average Spyglass Pharma stock price prediction forecasts a potential upside of 44.07% from the current SGP share price of $27.07.

What is SGP's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SGP) Spyglass Pharma's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that SGP's EPS will be -$2.43 for 2026, with the lowest EPS forecast at -$2.52, and the highest EPS forecast at -$2.18. On average, analysts forecast that SGP's EPS will be -$2.84 for 2027, with the lowest EPS forecast at -$3.38, and the highest EPS forecast at -$2.04. In 2028, SGP's EPS is forecast to hit -$3.09 (min: -$4.04, max: -$1.97).

What is SGP's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: SGP) forecast ROE is -41.73%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.